Nirsevimab Effectiveness Against RSV‐Related Hospitalisations in Children Under 24 Months: A Test‐Negative Case–Control Study in Portugal, 2024–2025

Résumé fourni par la source

We assessed Nirsevimab effectiveness (NE) against respiratory syncytial virus (RSV)-related hospitalisation in eligible children (< 2 years) using a test-negative case-control design within the VigiRSV network (weeks 43/2024 to 16/2025). Among 341 participants (median age: 2 months; 91.2% without known chronic condition), 137 (40.2%) tested RSV-positive. Adjusted NE against RSV-related hospitalisation was 78.5% (95%CI: 59.3-89.0). Sensitivity analyses confirmed the robustness of the results. These findings support Nirsevimab's effect in a predominantly healthy infant population and contribute to informing public health decisions for RSV immunisation.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.